research Repigmentation of hair following adalimumab therapy
A patient's grey hair regained color during treatment with adalimumab.
Search
for
Sort by
Research
420-450 / 1000+ resultsresearch Excimer lamp as an effective alternative treatment for severe alopecia areata
The excimer lamp is a safe and effective treatment for severe alopecia areata.
research Methotrexate in dermatology
Methotrexate is a key, cost-effective drug for skin conditions, but requires careful monitoring for side effects.
research Biologics in the management of childhood atopic dermatitis
Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
research Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS ) Database: A Real‐World Pharmacovigilance Study
Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
research Psoriatic onychopachydermoperiostitis: improvement with etanercept
Etanercept improved symptoms of a specific type of psoriatic arthritis in a patient who didn't respond to other treatments.
research 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
research 046 Analysing the mechanistic basis of Ritlecitinib’s therapeutic effects in Alopecia Areata
Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
research Efficacy of Intralesional Triamcinolone Acetonide Combined With Cryotherapy Compared to Intralesional Triamcinolone Acetonide Alone in Treating Limited Patchy Alopecia Areata of the Scalp and Face: A Prospective, Randomized, Within‐Subject Controlled Trial
Combining triamcinolone acetonide with cryotherapy may reduce scalp hair loss more than using triamcinolone alone.
research Novel therapies for alopecia areata: The era of rational drug development
New targeted therapies for hair loss from alopecia areata show promise, with personalized treatment expected in the future.
research 455 Beyond Immunity: TEC and JAK3 Kinase Activation in Melanocytes Drives Inflammation in Vitiligo
TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.
research A Chronic Contact Eczema Impedes Migration of Antigen-Presenting Cells in Alopecia Areata
Chronic contact eczema may help hair regrowth in alopecia areata by reducing certain immune cell movement.
research Tombo em João Pessoa dá força a Memorial da Arquitetura Paraibana
Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
research P4 Outcome following switch between brand name and generic tacrolimus in paediatric population
Switching to generic tacrolimus was safe, effective, and saved money.
research Efficacy and safety of ritlecitinib, an oral JAK3 /TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
research Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
research 565 Cutaneous delivery of LEKTI via an engineered strain of staphylococcus epidermidis for the treatment of netherton syndrome
ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.
research Rash from EGFR inhibitors: Opportunities and challenges for palliation
EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
research Guidelines for the Use of Acitretin in Psoriasis
Acitretin is effective for severe psoriasis and can be used long-term due to no immunosuppression, but must be carefully monitored for side effects and is not for pregnant women.
research A case of atopic dermatitis with self‐healing acute diffuse and total alopecia during nemolizumab treatment
research 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
research Alopecia areata after mogamulizumab treatment
Mogamulizumab can cause hair loss and skin rashes.
research EP06 Successful treatment of alopecia universalis with rituximab therapy
Rituximab therapy successfully treated a patient's complete body hair loss and was effective for six years.
research The new era of JAK inhibitors: Impelling updates in Alopecia Areata Guideline
research Ixekizumab Improved Refractory Erythrodermic Psoriasis with Comorbid Diffuse Alopecia: A Case Report with 52-Week Follow-Up
Ixekizumab effectively treated severe psoriasis and hair loss in a patient.
research Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
Apremilast shows promise for several skin conditions but needs more research.
research Incidence and management of cutaneous toxicities associated with cetuximab
Cetuximab often causes skin rashes, and managing these is important for cancer treatment.
research Sacituzumab Govitecan-Hziy (Trodelvy™)
Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
research Methotrexate Effectively Controls Ocular Inflammation in Japanese Patients With Non-infectious Uveitis
Methotrexate effectively controls eye inflammation in Japanese patients with non-infectious uveitis but requires careful monitoring for side effects.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.